# Patent

## Title
Applications of substituent benzyloxy group containing ether compounds for preparing antitumor drugs

## Abstract

Disclosed are applications of substituent benzyloxy group containing ether compounds represented by general formula I for preparing antitumor drugs.




The definition of the substituent groups in the formula I are provided in the specification.
The compounds having general formula I have desirable antitumor activity, particularly, and have excellent activity against leukemia strain HL-60, lung cancer A549, H157, H460, H520, bladder cancer T24, J82, prostate cancer LNCap, PC-3, rectal cancer HCT8, HCT116, RkO and the like.

## Background
FIELD OF THE INVENTION
The present invention belongs to the field of medicine, relating to the field of antitumor drugs. Specifically to applications of substituent benzyloxy group containing ether compounds for preparing antitumor drugs.
BACKGROUND OF THE INVENTION
The following journals and patents disclosed benzopyrone compounds containing methoxyacrylate with fungicidal activity in agrochemical field: Pest Management Science, Volume: 67, Issue: 6, Pages: 647-655; Natural Product Communications, Volume: 6, Issue: 12, Pages: 1917-1920; Nongyao, Volume: 50, Issue: 2, Pages: 90-92; Nongyaoxue Xuebao, Volume: 12, Issue: 4, Pages: 453-457; Natural Product Communications, Volume: 2, Issue: 8, Pages: 845-848; Chinese Chemical Letters, Volume: 22, Issue: 6, Pages: 663-666; WO 2005044813.
Journal of Medicinal Chemistry, Volume: 50, Issue: 12, Pages: 2886-2895 reported the following general formula containing benzopyrone group with antiplatelet activity.




Bioorganic & Medicinal Chemistry Letters 23(2013) 3505-3510 disclosed a strobilurin compound containing substituted pyrimidinamines with some antitumor activity, the structure of compound 96 (compound A in this patent) is as follows:




Patent U.S. Pat. No. 6,084,120 disclosed the compound having following general formula has some inhibition effect on Plasmodium falciparum NF54 strain and plasmodium berghei, however, compound B was reported at the same time without any biological data. Patent U.S. Pat. No. 7,947,734 also disclosed compound B (that is flufenoxystrobin) with good fungicidal and acaricidal activity in agrochmical field.




In the prior art, the substituent benzyloxy group containing ether compounds having the structure of general formula I were not reported as antitumor agents.
SUMMARY OF THE INVENTION
The object of the present invention is to provide substituent benzyloxy group containing ether compounds having general formula I, which can be applied to prepare antitumor drugs.
Detailed Description of the Invention is as Follows:
The application of substituent benzyloxy group containing ether compounds for preparing antitumor drugs, the compounds having the structure of general formula I:




Wherein:
Ar is selected from one of the following groups, Ar1 to Ar16:







Q is selected from one of the following groups, Q1 to Q22:







R1, R2, R3, R4, R5, R6 mutually independently may be the same or different, selected from H, halo, CN, NO2, OH, NH2, CHO, CO2H, CO2Na, CO2NH4, C1-C12alkyl, C1-C12haloalkyl, C3-C8cycloalkyl, C1-C12alkoxy, C1-C12haloalkoxy, C1-C12alkylthio, C1-C12haloalkylthio, C1-C12alkoxyC1-C12alkyl  haloC1-C12alkoxyC1-C12alkyl  C1-C12alkoxyC1-C12alkoxy  haloC1-C12alkoxyC1-C12alkoxy  C1-C12alkylthioC1-C12alkyl  haloC1-C12alkylthioC1-C12alkyl  C1-C12alkylamino  C1-C12haloalkylamino  C2-C12dialkylamino  C2-C12halodialkylamino  piperidinyl pyrrolidinyl N-methylpiperidinyl morpholinyl C2-C12alkenyl  C2-C12haloalkenyl C2-C12alkynyl  C2-C12haloalkynyl C2-C12alkenyloxy C2-C12haloalkenyloxy C2-C12alkynyloxy C2-C12haloalkynyloxy  C1-C12alkylsulfonyl  C1-C12haloalkylsulfonyl  C1-C12alkylsulfinyl  C1-C12haloalkylsulfinyl  C1-C12alkylcarbonyl  C1-C12haloalkylcarbonyl  C1-C12alkylcarbonyloxy  C1-C12alkylcarbonylamino  C1-C12alkylsulfonyloxy  C1-C12alkoxycarbonyl  C1-C12haloalkoxycarbonyl  C1-C12alkylaminosulfonyl  C1-C12alkoxycarbonylamino  C1-C12alkoxycarbonylC1-C12alkyl  C1-C12alkoxycarbonylC1-C12alkoxy  aminoC1-C12alkyl  C1-C12alkylaminoC1-C12alkyl  C2-C12dialkylaminoC1-C12alkyl C(═O)NR10R11  OC(═O)NR10R11  C(═S)NR10R11  SO2NR10R11  C(═NOR9)R8 or R7; or R1, R2 and carbon atom linked to them form five, six or seven-membered ring;
R7 is selected from unsubstituted or substituted phenyl, phenyloxy, phenyloxy C1-C12alkyl  phenylcarbonyl  phenyloxycarbonyl phenylaminocarbonyl phenylC1-C12alkyl phenylC1-C12alkoxy  phenylC1-C12alkoxyC1-C12alkyl naphthyl naphthyloxy  naphthyloxy C1-C12alkyl  naphthylcarbonyl  naphthyl C1-C12alkyl  naphthyl C1-C12alkoxy  naphthyl C1-C12alkoxyC1-C12alkyl heteroaryl heteroaryloxy heteroarylC1-C12alkoxyC1-C12alkyl heteroaryloxyC1-C12alkyl heteroarylcarbonyl heteroaryloxycarbonyl heteroarylaminocarbonyl heteroarylC1-C12alkyl or heteroarylC1-C12alkoxy, which is further mutually independently optionally substituted by 1 to 5 following group(s): halo  NO2 CN  SH  C1-C6alkyl  C1-C6 halo alkyl  C3-C8cycloalkyl  C1-C6alkoxy  C1-C6 halo alkoxy  C1-C6alkylthio  C1-C6 halo alkylthio  C2-C6alkenyl  C2-C6 halo alkenyl  C2-C6alkynyl  halo alkynyl  C3-C6alkenyloxy  C3-C6 halo alkenyloxy  C3-C6alkynyloxy  C3-C6 halo alkynyloxy  C1-C6alkylsulfinyl  C1-C6 halo alkylsulfinyl  C1-C6alkylsulfonyl  C1-C6 halo alkylsulfonyl  C1-C6alkoxyC1-C6alkyl  C1-C6alkylcarbonyl  C1-C6 halo alkylcarbonyl  C1-C6alkylcarbonyloxy  C1-C6alkylcarbonylamino  C1-C6alkylsulfonyloxy  C1-C6alkoxycarbonyl  C1-C6alkoxyC1-C6alkoxy  C1-C6alkoxycarbonylC1-C6alkyl  C1-C6alkoxycarbonylamino  C1-C6alkoxycarbonylC1-C6alkoxy  CHO  CO2H  CO2Na  CO2NH4  NR10R11  C(═O)NR10R11  OC(═O)NR10R11  C(═S)NR10R11 or SO2NR10R11:
R8, R9 is mutually independently selected from H  C1-C6alkyl  aryl or aryl C1-C6 alkyl;
R10, R11 mutually independently may be the same or different  selected from H  C1-C6alkyl  C1-C6 halo alkyl  C1-C6alkoxy  C1-C6 halo alkoxy  C1-C6alkylthio  C1-C6 halo alkylthio or C3-C8cycloalkyl;
And their stereoisomers.
The preferred substituent benzyloxy group containing ether compounds above compounds applied as antitumor drugs of general formula I of this invention are:
Ar is selected from Ar1  Ar2  Ar3  Ar4 or Ar16;
Q is selected from Q1  Q2  Q3  Q4  Q5  Q6  Q7  Q8  Q9  Q19  Q20  Q21 or Q22:
R1, R2, R3, R4, R5, R6 mutually independently may be the same or different, selected from H, halo, CN, NO2, OH, NH2, CHO, CO2H, CO2Na, CO2NH4, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkylthio, C1-C6haloalkylthio, C1-C6alkoxyC1-C6alkyl  haloC1-C6alkoxyC1-C6alkyl  C1-C6alkoxyC1-C6alkoxy  haloC1-C6alkoxyC1-C6alkoxy  C1-C6alkylthioC1-C6alkyl  haloC1-C6alkylthioC1-C6alkyl  C1-C6alkylamino  C1-C6haloalkylamino  C2-C8dialkylamino  C2-C8halodialkylamino  piperidinyl  pyrrolidinyl  N-methylpiperidinyl  morpholinyl  C2-C6alkenyl  C2-C6haloalkenyl  C2-C6alkynyl  C2-C6haloalkynyl  C2-C6alkenyloxy  C2-C6haloalkenyloxy  C2-C6alkynyloxy  C2-C6haloalkynyloxy  C1-C6alkylsulfonyl  C1-C6haloalkylsulfonyl  C1-C6alkylsulfinyl  C1-C6haloalkylsulfinyl  C1-C6alkylcarbonyl  C1-C6haloalkylcarbonyl  C1-C6alkylcarbonyloxyl  C1-C6alkylcarbonylamino  C1-C6alkylsulfonyloxy  C1-C6alkoxycarbonyl  C1-C6haloalkoxycarbonyl  C1-C6alkylaminosulfonyl  C1-C6alkoxycarbonylamino  C1-C6alkoxycarbonylC1-C6alkyl  C1-C6alkoxycarbonylC1-C6alkoxy  aminoC1-C6alkyl  C1-C6alkylaminoC1-C6alkyl  C2-C8dialkylaminoC1-C6alkyl  C(═O)NR10R11  OC(═O)NR10R11  C(═S)NR10R11  SO2NR10R11, C(═NOR9) R8 or R7; or R1, R2 and carbon atom linked to them form five or six-membered ring;
R7 is selected from unsubstituted or substituted phenyl, phenyloxy, phenyloxy C1-C6alkyl  phenylcarbonyl  phenyloxycarbonyl  phenylaminocarbonyl  phenylC1-C6alkyl  phenylC1-C6alkoxy  phenylC1-C6alkoxyC1-C6alkyl  naphthyl  naphthyloxy  naphthyloxy C1-C6alkyl  naphthylcarbonyl  naphthyl C1-C6alkyl  naphthyl C1-C6alkoxy  naphthylC1-C6alkoxyC1-C6alkyl  heteroaryl  heteroaryloxy  heteroarylC1-C6alkoxyC1-C6alkyl  heteroaryloxyC1-C6alkyl  heteroarylcarbonyl  heteroaryloxycarbonyl  heteroarylaminocarbonyl  heteroarylC1-C6alkyl or heteroarylC1-C6alkoxy, which is further mutually independently optionally substituted by 1 to 5 following group(s): halo  NO2  SH  C1-C4alkyl  C1-C4 haloalkyl  C3-C6cycloalkyl  C1-C4alkoxy  C1-C4 halo alkoxy  C1-C4alkylthio  C1-C4 halo alkylthio  C2-C4alkenyl  C2-C4 halo alkenyl  C2-C4alkynyl  C2-C4 halo alkynyl  C3-C4alkenyloxy  C3-C4halo alkenyloxy  C3-C4alkynyloxy  C3-C4 halo alkynyloxy  C1-C4alkylsulfinyl  C1-C4 halo alkylsulfinyl  C1-C4alkylsulfonyl  C1-C4 halo alkylsulfonyl  C1-C4alkoxyC1-C4alkyl  C1-C4alkylcarbonyl  C1-C4 halo alkylcarbonyl  C1-C4alkylcarbonyloxy  C1-C4alkylcarbonylamino  C1-C4alkylsulfonyloxy  C1-C4alkoxycarbonyl  C1-C4alkoxyC1-C4alkoxy  C1-C4alkoxycarbonylC1-C4alkyl  C1-C4alkoxycarbonylamino  C1-C4alkoxycarbonylC1-C4alkoxy  CHO  CO2H  CO2Na  CO2NH4  NR10R11  C(═O)NR10R11  OC(═O)NR10R11  C(═S)NR10R11 or SO2NR10R11:
R8, R9 is mutually independently selected from H  C1-C4alkyl  aryl or aryl C1-C4alkyl;
R10, R11 mutually independently may be the same or different  selected from C1-C4alkyl  C1-C4 halo alkyl  C1-C4alkoxy  C1-C4 halo alkoxy  C1-C4alkylthio  C1-C4 halo alkylthio or C3-C6cycloalkyl.
The preferred substituent benzyloxy group containing ether compounds above compounds applied as antitumor drugs of general formula I of this invention are:
Ar is selected from Ar1, Ar2, Ar3, Ar4 or Ar16;
Q is selected from Q1  Q2  Q3  Q4  Q5  Q6  Q7  Q8  Q9  Q19  Q20  Q21  or Q22:
R1, R2, R3, R4, R5, R6 mutually independently may be the same or different, selected from H, halo, CN, NO2, OH, NH2, CHO, CO2H, CO2Na, CO2NH4, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, C1-C4alkoxy, C1-C4haloalkoxy, C1-C4alkylthio, C1-C4haloalkylthio, C1-C4alkoxyC1-C4alkyl  haloC1-C4alkoxyC1-C4alkyl  C1-C4alkoxyC1-C4alkoxy  haloC1-C4alkoxyC1-C4alkoxy  C1-C4alkylthioC1-C4alkyl  haloC1-C4alkylthioC1-C4alkyl  C1-C4alkylamino  C1-C4haloalkylamino  C2-C6dialkylamino  C2-C6halodialkylamino  piperidinyl  pyrrolidinyl  N-methylpiperidinyl  morpholinyl  C2-C4alkenyl  C2-C4haloalkenyl  C2-C4alkynyl  C2-C4haloalkynyl  C2-C4alkenyloxy  C2-C4haloalkenyloxy  C2-C4alkynyloxy  C2-C4haloalkynyloxy  C1-C4alkylsulfonyl  C1-C4haloalkylsulfonyl  C1-C4alkylsulfinyl  C1-C4haloalkylsulfinyl  C1-C4alkylcarbonyl  C1-C4haloalkylcarbonyl  C1-C4alkylcarbonyloxy  C1-C4alkylcarbonylamino  C1-C4alkylsulfonyloxy  C1-C4alkoxycarbonyl  C1-C4haloalkoxycarbonyl  C1-C4alkylaminosulfonyl  C1-C4alkoxycarbonylamino  C1-C4alkoxycarbonylC1-C4alkyl  C1-C4alkoxycarbonylC1-C4alkoxy  aminoC1-C4alkyl  C1-C4alkylaminoC1-C4alkyl  C2-C6dialkylaminoC1-C4alkyl  C(═O)NR10R11  OC(═O)NR10R11  C(═S)NR10R11  SO2NR10R11  C(═NOR9)R8 or R7; or R1, R2 and carbon atom linked to them form saturated five or six-membered ring;
R7 is selected from unsubstituted or substituted phenyl  phenyloxy  phenyloxy C1-C4alkyl  phenylcarbonyl  phenyloxycarbonyl  phenylaminocarbonyl  phenylC1-C4alkyl  phenylC1-C4alkoxy  phenylC1-C4alkoxyC1-C4alkyl  naphthyl  naphthyloxy  naphthyloxy C1-C4alkyl  naphthylcarbonyl  naphthyl C1-C4alkyl  naphthyl C1-C4alkoxy  naphthylC1-C4alkoxyC1-C4alkyl  heteroaryl  heteroaryloxy  heteroarylC1-C4alkoxyC1-C4alkyl  heteroaryloxyC1-C4alkyl  heteroarylcarbonyl  heteroaryloxycarbonyl  heteroarylaminocarbonyl  heteroarylC1-C4alkyl or heteroarylC1-C4alkoxy  which is further mutually independently optionally substituted by 1 to 5 following group(s): halo  NO2  CN  SH  C1-C4alkyl  C1-C4 haloalkyl  C3-C6cycloalkyl  C1-C4alkoxy  C1-C4haloalkoxy  C1-C4alkylthio  C1-C4 halo alkylthio  C2-C4alkenyl  C2-C4 halo alkenyl  C2-C4alkynyl  C2-C4 halo alkynyl  C3-C4alkenyloxy  C3-C4halo alkenyloxy  C3-C4alkynyloxy  C3-C4 haloalkynyloxy  C1-C4alkylsulfinyl  C1-C4 halo alkylsulfinyl  C1-C4alkylsulfonyl  C1-C4 halo alkylsulfonyl  C1-C4alkoxyC1-C4alkyl  C1-C4alkylcarbonyl  C1-C4 halo alkylcarbonyl  C1-C4alkylcarbonyloxy  C1-C4alkylcarbonylamino  C1-C4alkylsulfonyloxy  C1-C4alkoxycarbonyl  C1-C4alkoxyC1-C4alkoxy  C1-C4alkoxycarbonylC1-C4alkyl  C1-C4alkoxycarbonylamino  C1-C4alkoxycarbonylC1-C4alkoxy  CHO  CO2H  CO2Na  CO2NH4  NR10R11  C(═O)NR10R11  OC(═O)NR10R11  C(═S)NR10R11 or SO2NR10R11:
R8, R9 is mutually independently selected from H  C1-C4alkyl  aryl or aryl C1-C4alkyl;
R10, R11 mutually independently may be the same or different  selected from H  C1-C4alkyl  C1-C4 haloalkyl  C1-C4alkoxyl  C1-C4 haloalkoxy  C1-C4alkylthio  C1-C4 haloalkylthio or C3-C6cycloalkyl.
Furthermore, the preferred substituent benzyloxy group containing ether compounds above compounds applied as antitumor drugs of general formula I of this invention are:
Ar is selected from Ar1  Ar2  Ar3 or Ar16;
Q is selected from Q1  Q2  Q3  Q4  Q5  Q6  Q7 or Q8;
R1, R2, R3, R4, R5, R6 mutually independently may be the same or different, selected from H, halo, CN, C1-C6alkyl, C1-C4haloalkyl, C3-C6cycloalkyl, C1-C4alkoxy, C1-C4haloalkoxy, C1-C4alkylthio, C1-C4alkoxyC1-C4alkyl  C1-C4alkylamino  C2-C6dialkylamino  C1-C4alkylsulfonyl or R7; or R1, R2 and carbon atom linked to them form saturated five or six-membered ring;

    
    
        R7 is selected from unsubstituted or substituted phenyl, benzyl, phenylethyl or heteroaryl, which is further mutually independently optionally substituted by 1 to 5 following group(s): halo  NO2  CN  C1-C4alkyl  C1-C4 haloalkyl  C1-C4alkoxy or C1-C4 haloalkoxy.
    
    


Furthermore, the preferred substituent benzyloxy group containing ether compounds above compounds applied as antitumor drugs of general formula I of this invention are:
Ar is selected from Ar1, Ar2, Ar3 or Ar16;
Q is Q1;
R1, R2, R3, R4, R5, R6 mutually independently may be the same or different, selected from H, halo, CN, C1-C6alkyl, C1-C4haloalkyl or R7; or R1, R2 and carbon atom linked to them form saturated five or six-membered ring;

    
    
        R7 is selected from unsubstituted or substituted phenyl, benzyl or heteroaryl, which is further mutually independently optionally substituted by 1 to 5 following group(s): halo  NO2  CN  C1-C4alkyl  C1-C4 haloalkyl  C1-C4alkoxy or C1-C4 haloalkoxy.
    
    


Furthermore, the preferred substituent benzyloxy group containing ether compounds above compounds applied as antitumor drugs of general formula I of this invention are:
Ar is selected from Ar3 or Ar16;
Q is Q1;
R1, R2, R3, R4, R5, R6 mutually independently may be the same or different, selected from H, halo, CN, C1-C6alkyl, C1-C4haloalkyl or R7; or R1, R2 and carbon atom linked to them form saturated five or six-membered ring;
R7 is selected from unsubstituted or substituted phenyl, benzyl or heteroaryl, which is further mutually independently optionally substituted by 1 to 5 following group(s): halo  NO2  CN  C1-C4alkyl  C1-C4 haloalkyl  C1-C4alkoxy or C1-C4 haloalkoxy.
Furthermore, the preferred substituent benzyloxy group containing ether compounds above compounds applied as antitumor drugs of general formula I of this invention are:

    
    
        Ar is selected from Ar3 or Ar16;
        Q is Q1;
        R1 is selected from H, halo or C1-C6alkyl;
        R2 is selected from C1-C4alkyl, C1-C4haloalkyl or R7;
        Or R1, R2 and carbon atom linked to them form saturated five or six-membered ring;
        R3, R4 are H;
        R6 is selected from H or C1-C4alkyl;
        R7 is selected from unsubstituted or substituted phenyl, which is further mutually independently optionally substituted by 1 to 3 following group(s); halo, CN, C1-C4alkyl, C1-C4 haloalkyl, C1-C4alkoxy or C1-C4 haloalkoxy.
    
    


Furthermore, the preferred substituent benzyloxy group containing ether compounds above compounds applied as antitumor drugs of general formula I of this invention are:

    
    
        Ar is selected from Ar3 or Ar16;
        Q is Q1;
        R1 is selected from H, halo or C1-C6alkyl;
        R2 is selected from C1-C4alkyl or R7;
        Or R1, R2 and carbon atom linked to them form saturated five or six-membered ring;
        R3, R4 are H;
        R6 is selected from H or C1-C4alkyl;
        R7 is selected from unsubstituted or substituted phenyl, which is further mutually independently optionally substituted by 1 to 3 following group(s): halo, C1-C4alkyl, C1-C4alkoxy or C1-C4 haloalkoxy.
    
    


The more preferred substituent benzyloxy group containing ether compounds above compounds applied as antitumor drugs of general formula I of this invention are:

    
    
        Ar is selected from Ar3 or Ar16;
        Q is Q1;
        R1 is selected from H, F or C1-C4alkyl;
        R2 is selected from C1-C4alkyl or phenyl;
        Or R1, R2 and carbon atom linked to them form saturated six-membered ring;
        R3, R4 are H;
        R6 is selected from H or CH3.
    
    


The most preferred substituent benzyloxy group containing ether compounds applied as antitumor drugs of general formula I of this invention are:

    
    
        Ar is selected from Ar3 or Ar16;
        Q is Q1;
        R1 is selected from H or C1-C4alkyl;
        R2 is selected from CH3 or phenyl;
        Or R1, R2 and carbon atom linked to them form saturated six-membered ring;
        R3, R4, R6 are H.
    
    


The terms used above to definite the compounds of general formula I represent substitutes as follow:
The “halogen” or “halo” is fluorine, chlorine, bromine or iodine.
The “alkyl” stands for straight or branched chain alkyl, such as methyl, ethyl, propyl, isopropyl or tert-butyl. The “haloalkyl” stands for straight or branched chain alkyl, in which hydrogen atoms can be all or partly substituted with halogen, such as chloromethyl, dichloromethyl, trichlororaethyl, fluoromethyl, difluoromethyl, trifluoromethyl, etc.
The “alkoxy” refers to straight or branched chain alkyl, which is linked to the structure by oxygen atom. The “haloalkoxy” refers to straight or branched chain alkoxy, in which hydrogen atoms may be all or partly substituted with halogen, such as chloromethoxy, dichloromethoxy, trichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chlorofluoromethoxy, trifluoroethoxy, etc.
The “alkylthio” refers to straight or branched chain alkyl, which is linked to the structure by sulfur atom. The “haloalkylthio” refers to straight or branched chain alkylthio, in which hydrogen atoms may be all or partly substituted with halogen, such as chloromethylthio, dichloromethylthio, trichloromethylthio, fluoromethylthio, difluoromethylthio, trifluoromethylthio, chlorofluoromethylthio, etc.
The “alkoxyalkyl” means alkoxy is linked to the structure by alkyl. Such as —CH2OCH2, —CH2OCH2CH3.
The “haloalkoxyalkyl” refers to alkoxyalkyl, in which hydrogen atoms may be all or partly substituted with halogen, such as —CH2OCH2CH2Cl.
The “alkoxyalkoxy” means OCH2OCH2CH3 etc. The “haloalkoxyalkoxy” means —OCH2OCH2CH2Cl etc.
The “alkylthioalkyl” means alkylthio is linked to the structure by alkyl. Such as —CH2SCH2.
The “haloalkylthioalkyl” means haloalkylthio is linked to the structure by alkyl.
The “alkylamino” refers to straight or branched chain alkyl, which is linked to the structure by nitrogen atom.
The “haloalkylamino” refers to straight or branched chain alkylamino, in which hydrogen atoms may be all or partly substituted with halogen.
The alkenyl refers to straight or branched chain alkenyl, such as ethenyl, 1-propenyl, 2-propenyl and different isomer of butenyl, pentenyl and hexenyl. Alkenyl also includes polyene, such as propa-1,2-dienyl and hexa-2,4-dienyl. The haloalkenyl stands for straight or branched chain alkenyl, in which hydrogen atoms can be all or partly substituted with halogen. The alkynyl refers to straight or branched chain alkynyl, such as ethynyl, 1-propynyl and different isomer of butynyl, pentynyl and hexynyl. Alkynyl also includes groups including more than one triple bonds, such as hexa-2,5-diynyl. The “haloalkynyl” stands for straight or branched chain alkynyl, in which hydrogen atoms can be all or partly substituted with halogen.
The alkenoxyl refers to straight or branched chain alkynes is linked to the structure by oxygen, such as propenyloxy. The haloalkenoxyl stands for a straight-chain or branched alkenoxyl, in which hydrogen atoms may be all or partly substituted with halogen. The alkynoxyl refers to straight or branched chain alkynes is linked to the structure by oxygen, such as propynyloxy. The haloalkynoxyl stands for a straight-chain or branched alkynoxyl, in which hydrogen atoms may be all or partly substituted with halogen.
The “alkylsulfonyl” means a straight-chain or branched alkyl is linked to the structure by (—SO2—), such as methylsulfonyl. The “haloalkylsulfonyl” stands for a straight-chain or branched alkylsulfonyl, in which hydrogen atoms may be all or partly substituted with halogen.
The “alkylsulfinyl” means a straight-chain or branched alkyl is linked to the structure by (—SO—), such as methylsulfinyl.
The “haloalkylsulfinyl” stands for a straight-chain or branched alkylsulfinyl, in which hydrogen atoms may be all or partly substituted with halogen.
The “alkylcarbonyl” means alkyl is linked to the structure by carbonyl. such as CH3CO—, CH3CH2CO—.
The “haloalkylcarbonyl” stands for a straight-chain or branched alkylcarbonyl, in which hydrogen atoms may be all or partly substituted with halogen, such as CF3CO—.
The “alkylcarbonyloxy” means CH3COO—, CH3CH2NHCOO— etc. The “alkylcarbonylamino” means CH3CONH—, CH3CH2NHCONH— etc.
The “alkylsulfonyloxy” means alkyl-S(O)2—O—. The “alkoxycarbonyl” means alkyl-O—CO—.
The “haloalkoxycarbonyl” stands for alkoxycarbonyl, in which hydrogen atoms can be all or partly substituted with halogen, such as —COOCH2CF3, —COOCH2CH2Cl.
The “alkylaminosulfonyl” means —S(O)2NHCH3, —S(O)2NHCH2CH3 etc. The “alkoxycarbonylamino” means —NHCOOCH3, —NHCOOCH2CH3 etc. The “alkoxycarbonylalkyl” means —CH2COOCH3, —CH2COOCH2CH3 etc. The “alkoxycarbonylalkoxy” means —OCH2COOCH3, —OCH2COOCH2CH3 etc. The “aminoalkyl” such as —CH2NH2, —CH2CH2NH2. The “alkylaminoalkyl” such as CH2NHCH3, —CH2NHCH2CH3. The “dialkylaminoalkyl” such as —CH2NH(CH3)2 etc.
The “aryl” in terms of (hetero)aryl, (hetero)aryloxy, (hetero)arylalkoxyalkyl, (hetero)aryloxyalkyl, (hetero)arylcarbonyl, (hetero)aryloxycarbonyl, (hetero)arylaminocarbonyl, (hetero)arylalkyl or (hetero)arylalkoxy include phenyl or naphthyl etc.
The heteroaryl stands for five member ring or six member ring containing one or more N, O, S hetero atoms. Such as pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, thiazolyl, quinolinyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrazolyl, pyranyl, triazolyl, tetrazolyl, benzothiazolyl, benzofuranyl, etc. The (hetero)aryloxy such as phenyloxy, pyridinyloxy, pyrimidinyloxy, quinolinyloxy, eye.
The (hetero)arylalkoxyalkyl means —CH2OCH2Ph, 6-chloropyridin-3-ylmethoxyl, etc. The (hetero)aryloxyalkyl means, —CH2OPh, 4,6-(OCH3)2-2-yloxyethyl, etc. The (hetero)arylcarbonyl means PhCHO, 4-ClPhCHO, etc. The (hetero)aryloxycarbonyl means PhOCO, 4-ClPhOCO, 4-NO2PhOCO, Naph OCO, etc. The (hetero)arylaminocarbonyl, (hetero)arylalkyl or (hetero)arylalkoxy includes phenyl or naphthyl etc.
The compounds of the present invention can form stereoisom (Z- and E-isomer respectively) due to the existing of C═C and C═N bonds. The invention includes Z-isomer and E-isomer and their mixture at any ratio.
The drugs were made from the active ingredients of general formula I substituent benzyloxy group containing ether compounds, which can dose by oral medication or parenteral route, also by implantable medication pump and other methods.
The substituent benzyloxy group containing ether compounds having the general formula I in present invention can be used to prepare the drugs for curing or alleviating the cancer. The formulations include tablets, pills, capsule, granule, syrup, injection or freeze-dried powder injection.
Furthermore, the substituent benzyloxy group containing ether compounds having the general formula I in present invention can be used to cure or alleviate the cancer causing by cancer cells of human tissue or organ. The cancers include but not limited to colon cancer, liver cancer, lymph cancer, lung cancer, esophageal cancer, breast cancer, central nervous system cancer, melanoma, ovarian cancer, cervical cancer, renal cancer, leukemia, prostatic cancer, pancreatic cancer, bladder cancer, rectal cancer or stomach cancer.
Part of the substitutes of R1, R2, R3, R4, R5 and R6 in formula I are separately listed in table 1, but without being restricted thereby.











TABLE 1







substitute R1 (R2, R3, R4, R5, R6)










R1 (R2, R3, R4,
R1 (R2, R3, R4,
R1 (R2, R3, R4, R5,



R5, R6)
R5, R6)
R6)
R1 (R2, R3, R4, R5, R6)





H
NH(CH2)3CH3
OCONHCH2CH3
Ph-2,3-2CN-4,5,6-3Cl


F
NHC(CH3)3
OCON(CH2CH3)2
Ph-2,3-2CN-3,5,6-3Cl


 


Cl




OCONH(CH2)2CH3
OPh


 


Br




OCONHCH(CH3)2
CONHPh-2-Cl-4-CF3


 


I




OCONH(CH2)3CH3
CONHPh-2-Cl-4-NO2


 


CN




OCONHC(CH3)3
CH2Ph


 


NO2
CH2CH═CH2
CSNH2
CH2—Ph-4-Cl


OH
CH2CH═CF2
CSNHCH3
CH2CH2Ph


NH2
CH2CH2CH═CF2
CSN(CH3)2
CH2CH2—Ph-4-Cl


CHO
CH2CH2CF═CF2
CSNHCH2CH3
OCH2Ph


COOH
CH2CH═CCl2
CSN(CH2CH3)2
OCH2CH2Ph


CO2Na
CH2C≡CH
CSNH(CH2)2CH3
CH2OCH2Ph


CO2NH4
CH2C≡C—I
CSNHCH(CH3)2
CH2OCH2CH2Ph


CH3
CH2C≡C—Cl
CSNH(CH2)3CH3
CH2OPh


CH2CH3
CH2C≡CCH3
CSNHC(CH3)3
naphthyloxy


n-C3H7
OCH2CH═CH2
SO2NH2
naphthylmethyl


i-C3H7
OCH2CH═CCl2
SO2NHCH3
6-chloropyridin-3-yl


i-C3H7CH2CH2
OCH2C≡CH
SO2N(CH3)2
3-Cl-5-CF3-pyridin-2-yl


n-C4H9
SO2CH3
C(═NOCH3)CH3
5-CF3-pyridin-2-yl


i-C4H9
SO2CH2CH3
Ph
3,5,6-Cl3-pyridin-2-yl


n-C5H11
SOCH3
Ph-2-F
3,5-Cl2-pyridin-2-yl


n-C6H13
SOCH3CH3
Ph-3-F
5-OCF3-pyridin-2-yl


CH2Bu-t
COCH3
Ph-4-F
6-Cl-pyridazin-3-yl


CF3
COCH2CH3
Ph-2-Cl
6-CF3-pyridazin-3-yl


CHF2
COCF3
Ph-3-Cl
6-OCF3-pyridazin-3-yl


CH2F
COCH2Cl
Ph-4-Cl
3-Cl-pyrazin-2-y


CH2Cl
COCH2CH2Cl
Ph-4-CH3
6-Cl-pyrazin-2-y


CH2Br
OCOCH3
Ph-3-CH3
pyrimidin-2-yl


CH2CF3
OCOCH2CH3
Ph-2-OCH3
pyrimidin-4-yl


CF2CHF2
NHCOCH3
Ph-3-OCH3
pyrimidin-5-yl


CF2CF3
NHCOCH2CH3
Ph-4-OCH3
5-Cl-pyrimidin-2-yl


 






OSO2CH3
Ph-2-CF3
5-CF3-pyrimidin-2-yl


 






OSO2CH2CH3
Ph-3-CF3
5-OCH3—CO-pyridin-2-yl


 






CO2CH3
Ph-4-CF3
4,6-(CH3)2-pyrimidin-2-yl


 


OCH3
CO2CH2CH3
Ph-2-OCF3
4,6-(OCH3)2-pyrimidin-2-yl


OCH2CH3
CO2CH2CH2Cl
Ph-3-OCF3
4,6-(CH3)2-triazin-2-yl


O(CH2)2CH3
SO2NH2
Ph-4-OCF3
4,6-(OCH3)2-triazin-2-yl


OCH(CH3)2
SO2NHCH3
Ph-4-NO2
5-Cl-benzoxazol-2-yl


OCF3
SO2N(CH3)2
Ph-4-CN
6-Cl-quinoxalin-2-yl


OCH2CF3
NHCOOCH3
Ph-4-t-Bu
4-CH3-benzyl


OCF2CF3
NHCOOCH2CH3
Ph-2,4-2Cl
2-CN-benzyl


SCH3
CH2CO2CH3
Ph-2,4-2F
2-Cl-6-F-benzyl


CH2OCH3
CH2CO2CH2CH3
Ph-3,5-2Cl
2,5-Cl2-benzyl


CH2OCH2CH3
OCH2CO2CH3
Ph-3,4-2Cl
6-Cl-pyridin-3-ylmethyl


CH2OCH2Cl
CH2NHCH3
Ph-2,3-2Cl
2-Ck-thiazol-5-ylmethyl


CH2OCH2CHF2
CH2N(CH3)2
Ph-2,5-2Cl
benzoxazol-2-yloxy


CH2OCH2CF3
CONH2
Ph-2,6-2Cl
5-Cl-benzoxazol-2-ylmethyl


CH2SCH3
CONHCH3
Ph-2-CH3-4-Cl
3-Cl-5-CF3-pyridin-2-yloxy


CH2SCH2CH3
CON(CH3)2
Ph-2-Cl-4-CF3
6-Cl-pyridn-3-ylmethoxyl


CH2SCH2Cl
CONHCH2CH3
Ph-3,4-(OMe)2
2-Cl-thiazol-5-ylmethoxy


CH2SCH2CHF2
CON(CH2CH3)2
Ph-2,6-2Cl-4-CF3
5-CH2Cl-pyridin-2-yloxymethyl


NHCH3
CONH(CH2)2CH3
Ph-2,6-2Cl-4-NO2
6-Cl-pyridin-3-ylmethoxymethyl


N(CH3)2
CONHCH(CH3)2
Ph-2,4,6-3Cl
6-Cl-pyridn-3-yl(C═O)


NHCH2CH3
CONH(CH2)3CH3
Ph-2,4,6-3CH3
pyridn-2-ylO(C═O)


N(CH2CH3)2
CONHC(CH3)3
Ph-2-CH3-3-Cl-4,6-2NO2
pyridn-3-yl NH(C═O)


NH(CH2)2CH3
OCONHCH3
Ph-3-Cl-2,6-2NO2-4-CF3



NHCH(CH3)2
OCON(CH3)2
Ph-2,5-2CN-3,4,6-3Cl








R1, R2










CH2CH2CH2
CH2CH2CH2CH2
CH2CH2CH2CH2CH2










The present invention is also explained by the following compounds having general formula I with antitumor activity in Table 2-Table 53, but without being restricted thereby.
When Ar is Ar1, Q is Q1, the presentitive compounds 2-1 to 2-112 are listed in Table 2.







TABLE 2







substituents when Ar = Ar1








 












No.
R1
R3
R4
R5
R6





2-1
H
H
H
H
H


2-2
CH3
H
H
H
H


2-3
C2H5
H
H
H
H


2-4
i-C3H7
H
H
H
H


2-5
n-C3H7
H
H
H
H


2-6
n-C4H9
H
H
H
H


2-7
t-C4H9
H
H
H
H


2-8
OCH3
H
H
H
H


2-9
OC2H5
H
H
H
H


2-10
CH2Cl
H
H
H
H


2-11
CH2NH2
H
H
H
H


2-12
CH2CH2NH2
H
H
H
H


2-13
CH2CH2CN
H
H
H
H


2-14
NH2
H
H
H
H


2-15
NO2
H
H
H
H


2-16
OH
H
H
H
H


2-17
CO2H
H
H
H
H


2-18
F
H
H
H
H


2-19
Cl
H
H
H
H


2-20
Br
H
H
H
H


2-21
I
H
H
H
H


2-22
CH2—CH═CH2
H
H
H
H


2-38
CH2—C≡CH
H
H
H
H


2-39
H
CH3
H
H
H


2-40
H
C2H5
H
H
H


2-41
H
i-C3H7
H
H
H


2-42
H
n-C3H7
H
H
H


2-43
H
n-C4H9
H
H
H


2-44
H
t-C4H9
H
H
H


2-45
H
OCH3
H
H
H


2-46
H
OC2H5
H
H
H


2-47
H
CH2Cl
H
H
H


2-48
H
CO2H
H
H
H


2-49
H
F
H
H
H


2-50
H
Cl
H
H
H


2-51
H
Br
H
H
H


2-52
H
I
H
H
H


2-53
H
Ph
H
H
H


2-54
H
H
CH3
H
H


2-55
H
H
C2H5
H
H


2-56
H
H
i-C3H7
H
H


2-57
H
H
n-C3H7
H
H


2-58
H
H
n-C4H9
H
H


2-59
H
H
t-C4H9
H
H


2-60
H
H
OCH3
H
H


2-61
H
H
OC2H5
H
H


2-62
H
H
NH2
H
H


2-63
H
H
OH
H
H


2-64
H
H
CO2H
H
H


2-65
H
H
F
H
H


2-66
H
H
Cl
H
H


2-67
H
H
Br
H
H


2-68
H
H
I
H
H


2-69
H
H
Ph
H
H


2-70
H
H
H
CH3
H


2-71
H
H
H
C2H5
H


2-72
H
H
H
i-C3H7
H


2-73
H
H
H
n-C3H7
H


2-74
H
H
H
n-C4H9
H


2-75
H7
H
H
t-C4H9
H


2-76
H
H
H
OCH3
H


2-77
H
H
H
OC2H5
H


2-78
H
H
H
CH2Cl
H


2-79
H
H
H
N(CH3)2
H


2-80
H
H
H
OCOOCH3
H


2-81
H
H
H
OCOCH3
H


2-82
H
H
H
NH2
H


2-83
H
H
H
CN
H


2-84
H
H
H
OH
H


2-85
H
H
H
CO2H
H


2-86
H
H
H
F
H


2-87
H
H
H
Cl
H


2-88
H
H
H
Br
H


2-89
H
H
H
I
H


2-90
H
H
H
CH2—CH═CH2
H


2-91
H
H
H
CH2—C≡CH
H


2-92
H
H
H
H
CH3


2-93
H
H
H
H
C2H5


2-94
H
H
H
H
OCH3


2-95
H
H
H
H
CHO


2-96
H
H
H
H
F


2-97
H
H
H
H
Cl


2-98
H
H
H
H
Br


2-99
H
H
H
H
I


2-100
H
H
H
H
Ph


2-101
H
H
H
H
CH2Ph


2-102
CH3
H
H
H
CH3


2-103
H
H
CH3
CH3
H


2-104
H
H
CH3
H
CH3


2-105
H
H
OCH3
H
OCH3


2-106
H
H
Cl
H
Cl


2-107
H
H
H
CH3
CH3


2-108
CH3
H
H
CH3
H


2-109
H
H
Cl
CH3
H


2-110
H
H
C2H5
C2H5
H


2-111
CH3
H
CH3
H
H


2-112
H
CH3
CH3
H
CH3









Table 3: When Ar is Ar1, Q is Q2, the substituents of presentitive compounds 3-1 to 3-112 are consistent with 2-1 to 2-112 in Table 2;
Table 4: When Ar is Ar1, Q is Q3, the substituents of presentitive compounds 4-1 to 4-112 are consistent with 2-1 to 2-112 in Table 2;
Table 5: When Ar is Ar1, Q is Q4, the substituents of presentitive compounds 5-1 to 5-112 are consistent with 2-1 to 2-112 in Table 2;
Table 6: When Ar is Ar1, Q is Q5, the substituents of presentitive compounds 6-1 to 6-112 are consistent with 2-1 to 2-112 in Table 2;
Table 7: When Ar is Ar1, Q is Q6, the substituents of presentitive compounds 7-1 to 7-112 are consistent with 2-1 to 2-112 in Table 2;
Table 8: When Ar is Ar1, Q is Q7, the substituents of presentitive compounds 8-1 to 8-112 are consistent with 2-1 to 2-112 in Table 2;
Table 9: When Ar is Ar1, Q is Q8 is the substituents of presentitive compounds 9-1 to 9-112 are consistent with 2-1 to 2-112 in Table 2;
Table 10: When Ar is Ar1, Q is Q9, the substituents of presentitive compounds 10-1 to 10-112 are consistent with 2-1 to 2-112 in Table 2;
Table 11: When Ar is Ar1, Q is Q19, the substituents of presentitive compounds 11-1 to 11-112 are consistent with 2-1 to 2-112 in Table 2;
Table 12: When Ar is Ar1, Q is Q20, the substituents of presentitive compounds 12-1 to 12-112 are consistent with 2-1 to 2-112 in Table 2;
Table 13: When Ar is Ar1, Q is Q21, the substituents of presentitive compounds 13-1 to 13-112 are consistent with 2-1 to 2-112 in Table 2;
Table 14: When Ar is Ar1, Q is Q22, the substituents of presentitive compounds 14-1 to 14-112 are consistent with 2-1 to 2-112 in Table 2.
When Ar is Ar2, Q is Q1, the presentitive compounds 15-1 to 15-121 are listed in Table 15.







TABLE 15







substituents when Ar = Ar2








 












No.
R1
R2
R3
R5
R6





15-1
H
H
H
H
H


15-2
CH3
H
H
H
H


15-3
C2H5
H
H
H
H


15-4
i-C3H7
H
H
H
H


15-5
n-C3H7
H
H
H
H


15-6
n-C4H9
H
H
H
H


15-7
t-C4H9
H
H
H
H


15-8
OH
H
H
H
H


15-9
NH2
H
H
H
H


15-10
CN
H
H
H
H


15-11
NO2
H
H
H
H


15-12
CHO
H
H
H
H


15-13
CO2H
H
H
H
H


15-14
COCH3
H
H
H
H


15-15
CONH2
H
H
H
H


15-16
COOCH3
H
H
H
H


15-17
CH2COCH3
H
H
H
H


15-18
CH2—CH═CH2
H
H
H
H


15-19
C(CH3)2—CH═CH2
H
H
H
H


15-20
4-Cl—Ph
H
H
H
H


15-21
4-CH3—Ph
H
H
H
H


15-22
H
CH3
H
H
H


15-23
H
C2H5
H
H
H


15-24
H
i-C3H7
H
H
H


15-25
H
n-C3H7
H
H
H


15-26
H
n-C4H9
H
H
H


15-27
H
t-C4H9
H
H
H


15-28
H
OCH3
H
H
H


15-29
H
OC2H5
H
H
H


15-30
H
CH2Cl
H
H
H


15-31
H
CH2NH2
H
H
H


15-32
H
CH2CH2NH2
H
H
H


15-33
H
COOCH3
H
H
H


15-34
H
COCH3
H
H
H


15-35
H
CH2COCH3
H
H
H


15-36
H
OH
H
H
H


15-37
H
4-t-C4H9—Ph
H
H
H


15-38
H
4-Cl—Ph
H
H
H


15-39
H
4-CH3—Ph
H
H
H


15-40
H
H
CH3
H
H


15-41
H
H
C2H5
H
H


15-42
H
H
i-C3H7
H
H


15-43
H
H
n-C3H7
H
H


15-44
H
H
n-C4H9
H
H


15-45
H
H
t-C4H9
H
H


15-46
H
H
OH
H
H


15-47
H
H
NH2
H
H


15-48
H
H
CN
H
H


15-49
H
H
NO2
H
H


15-50
H
H
CHO
H
H


15-51
H
H
CO2H
H
H


15-52
H
H
COCH3
H
H


15-53
H
H
CH2N(CH3)2
H
H


15-54
H
H
CH2—CH═CH2
H
H


15-55
H
H
C(CH3)2—CH═CH2
H
H


15-56
H
H
F
H
H


15-57
H
H
Cl
H
H


15-58
H
H
Br
H
H


15-59
H
H
I
H
H


15-60
H
H
H
CH3
H


15-61
H
H
H
C2H5
H


15-62
H
H
H
i-C3H7
H


15-63
H
H
H
n-C3H7
H


15-64
H
H
H
n-C4H9
H


15-65
H
H
H
t-C4H9
H


15-66
H
H
H
OCH3
H


15-67
H
H
H
OC2H5
H


15-68
H
H
H
CH2Cl
H


15-69
H
H
H
COCH3
H


15-70
H
H
H
NH2
H


15-71
H
H
H
NO2
H


15-72
H
H
H
OH
H


15-73
H
H
H
OCOCH3
H


15-74
H
H
H
F
H


15-75
H
H
H
Cl
H


15-76
H
H
H
Br
H


15-77
H
H
H
I
H


15-78
H
H
H
CH2—CH═CH2
H


15-79
H
H
H
CH2—C≡CH
H


15-80
H
H
H
H
CH3


15-81
H
H
H
H
C2H5


15-82
H
H
H
H
i-C3H7


15-83
H
H
H
H
n-C3H7


15-84
H
H
H
H
n-C4H9


15-85
H
H
H
H
t-C4H9


15-86
H
H
H
H
OCH3


15-87
H
H
H
H
OC2H5


15-88
H
H
H
H
OH


15-89
H
H
H
H
C(NOCH3)CH3


15-90
H
H
H
H
F


15-91
H
H
H
H
Cl


15-92
H
H
H
H
Br


15-93
H
H
H
H
I


15-94
H
H
H
H
CH2—CH═C(CH3)2


15-95
H
CH3
H
H
CH3


15-96
H
Ph
H
H
CH3


15-97
H
Ph
H
H
OCH3


15-98
H
CH2Cl
H
H
Ph


15-99
H
H
CH3
H
CH3


15-100
H
H
OCH3
H
OCH3


15-101
CH3
H
H
OCH3
H


15-102
CH3
H
H
CH═CH2Ph
H


15-103
H
CH3
CH3
H
H


15-104
CH3
CH3
H
H
H


15-105
Ph
CH3
H
H
H


15-106
H
CH3
OCH3
H
H


15-107
H
CH3
Cl
H
H


15-108
H
CH3
H
H
t-C4H9


15-109
H
H
H
OCH3
OCH3


15-110
H
H
CH3
CH3
CH3


15-111
H
CH3
H
CH3
CH3


15-112
CH3
CH3
H
CH3
H


15-113
H
H
OCH3
OCH3
OCH3











15-114
CH2CH2CH2
H
H
H


15-115
CH2CH2CH2
H
H
CH3


15-116
CH2CH2CH2
H
CH3
H


15-117
CH2CH2CH2
H
Ph
H


15-118
CH2CH2CH2CH2
H
H
H


15-119
CH2CH2CH2CH2
H
H
CH3


15-120
CH2CH2CH2CH2
H
CH3
H


15-121
CH2CH2CH2CH2
H
Ph
H









Table 16: When Ar is Ar2, Q is Q2, the substituents of presentitive compounds 16-1 to 16-121 are consistent with 15-1 to 15-121 in Table 15;
Table 17: When Ar is Ar2, Q is Q3, the substituents of presentitive compounds 17-1 to 17-121 are consistent with 15-1 to 15-121 in Table 15;
Table 18: When Ar is Ar2, Q is Q4, the substituents of presentitive compounds 18-1 to 18-121 are consistent with 15-1 to 15-121 in Table 15;
Table 19: When Ar is Ar2, Q is Q5, the substituents of presentitive compounds 19-1 to 19-121 are consistent with 15-1 to 15-121 in Table 15;
Table 20: When Ar is Ar2, Q is Q6, the substituents of presentitive compounds 20-1 to 20-121 are consistent with 15-1 to 15-121 in Table 15;
Table 21: When Ar is Ar2, Q is Q7, the substituents of presentitive compounds 21-1 to 21-121 are consistent with 15-1 to 15-121 in Table 15;
Table 22: When Ar is Ar2, Q is Q8, the substituents of presentitive compounds 22-1 to 22-121 are consistent with 15-1 to 15-121 in Table 15;
Table 23: When Ar is Ar2, Q is Q9, the substituents of presentitive compounds 23-1 to 23-121 are consistent with 15-1 to 15-121 in Table 15;
Table 24: When Ar is Ar2, Q is Q19, the substituents of presentitive compounds 24-1 to 24-121 are consistent with 15-1 to 15-121 in Table 15;
Table 25: When Ar is Ar2, Q is Q20, the substituents of presentitive compounds 25-1 to 25-121 are consistent with 15-1 to 15-121 in Table 15;
Table 26: When Ar is Ar2, Q is Q21, the substituents of presentitive compounds 26-1 to 26-121 are consistent with 15-1 to 15-121 in Table 15;
Table 27: When Ar is Ar2, Q is Q22, the substituents of presentitive compounds 27-1 to 27-121 are consistent with 15-1 to 15-121 in Table 15;
When Ar is Ar3, Q is Q1, the presentitive compounds 28-1 to 28-139 are listed in Table 28.







TABLE 28







substituents when Ar = Ar3








 











NO.
R1
R2
R4
R6





28-1
H
H
H
H


28-2
H
CH3
H
H


28-3
H
CH3
H
CH3


28-4
H
Ph
H
CH3


28-5
CH3
CH3
H
H


28-6
CH3
CH3
H
CH3


28-7
H
CF3
H
H


28-8
H
CH3
H
E


28-9
H
CH3
E
H


28-10
H
CH3
COCH3
H


28-11
H
CH3
H
COCH3


28-12
Cl
CH3
H
H


28-13
H
CH2Cl
H
H


28-14
Cl
CH2Cl
H
H


28-15
Cl
CH2OCH3
H
H


28-16
Cl
CH2CH3
H
H


28-17
H
CH2CH3
H
CH3


28-18
C2H5
CH3
H
H


28-19
H
CH2OCH3
H
H


28-20
H
CH2OC2H5
H
H


28-21
Cl
CH2OC2H5
H
H


28-22
OCH3
CH2OCH3
H
H


28-23
N(CH3)2
CH3
H
H


28-24
CN
H
H
H


28-25
Cl
CH3
H
CH3


28-26
H
CH(CH3)2
H
H


28-27
C3H7
CH3
H
H


28-28
H
t C4H9
H
H


28-29
H
4-Cl—Ph
H
H


28-30
Cl
4-Cl—Ph
H
H


28-31
H
4-Cl—Ph
H
CH3


28-32
Cl
Ph
H
H


28-33
H
CH2CH3
H
H


28-34
H
CH2C2H5
H
H


28-35
H
CH2C2H5
H
CH3


28-36
Cl
CH2C2H5
H
H


28-37
CH3
CH2C2H5
H
H


28-38
H
4-F—Ph
H
H


28-39
Cl
4-F—Ph
H
H


28-40
H
4-F—Ph
H
CH3


28-41
H
4-CF3—Ph
H
H


28-42
Cl
4-CF3—Ph
H
H


28-43
Cl
CH2N(CH3)2
H
H


28-44
OCH3
C2H5
H
H


28-45
OCH3
CH3
H
H


28-46
OC2H5
CH3
H
H


28-47
H
CH2OCH2CF3
H
H


28-48
Cl
CH2OCH2CF3
H
H


28-49
F
CF3
H
H


28-50
F
CH3
H
H


28-51
H
CH2N(CH3)2
H
H


28-52
H
Ph
H
H


28-53
Cl
Cl
H
H


28-54
F
Cl
H
H


28-55
H
CH2OCH2Ph
E
H


28-56
OCH3
4-Cl—Ph
H
H


28-57
F
4-Cl—Ph
H
H


28-58
H
M
H
H


28-59
Cl
M
H
H


28-60
Cl
M
H
CH3


28-61
CH2S
CH3
H
H


28-62
CH3SO2
CH3
H
H


28-63
F
F
H
H


28-64
CH3SO2
Cl
H
H


28-65
H
4-NO2—Ph
H
H


28-66
Cl
4-NO2—Ph
H
H


28-67
H
4-NO2—Ph
H
CH3


28-68
PhCH2
CH3
H
H


28-69
PhCH2
CH3
H
CH3


28-70
CF3CH2O
C3H7
H
H


28-71
i-C3H7
CH3
H
H


28-72
n-C6H13
CH3
H
H


28-73
n-C5H11
CH3
H
H


28-74
C2H4—i-Pr
CH3
H
H


28-75
n-C6H13
CH3
H
H


28-76
H
n-C4H9
H
H


28-77
H
n-C5H11
H
H


28-78
H
CH(CH3)2
H
CH3


28-79
n-C3H7
n-C3H7
H
H


28-80
CH3
n-C4H9
H
H


28-81
C2H5
n-C4H9
H
H


28-82
C3H7
n-C4H9
H
H


28-83
i-C3H7
n-C4H9
H
H


28-84
n-C4H9
n-C4H9
H
H


28-85
CH3
n-C5H11
H
H


28-86
C2H5
n-C5H11
H
H


28-87
C3H7
n-C5H11
H
H


28-88
i-C3H7
n-C5H11
H
H


28-89
n-C4H9
n-C5H11
H
H


28-90
H
n-C6H13
H
H


28-91
CH3
n-C6H13
H
H


28-92
C2H5
n-C6H13
H
H


28-93
C3H7
n-C6H13
H
H


28-94
i-C3H7
n-C6H13
H
H


28-95
n-C4H9
n-C6H13
H
H


28-96
H
CH2—Ph-4-Cl
H
H


28-97
CH3
CH2—Ph-4-Cl
H
H


28-98
C2H5
CH2—Ph-4-Cl
H
H


28-99
CH2—Ph-4-Cl
CH3
H
H


28-100
CH2—Ph-4-Cl
C2H5
H
H


28-101
CH2—Ph-4-Cl
C3H7
H
H


28-102
CH3
CF3
H
H


28-103
Cl
CF3
H
H


28-104
C2H5
CF3
H
H


28-105
n-C3H7
CF3
H
H


28-106
n-C4H9
CF3
H
H


28-107
H
CH2CH2—Ph-
H
H


28-108
CH3
4-Cl
H
H


28-109
H
CH2Bu-t
H
H


28-110
CH3
CH2Bu-t
H
H


28-111
n-C3H7
CH2Bu-t
H
H


28-112
CH2Bu-t
CH3
H
H


28-113
CH2CH2—Ph-
CH3
H
H


28-114
4-Cl
C2H5
H
H


28-115

C3H7
H
H


28-116
CO2CH3
CH3
H
H


28-117
CO2CH3
CF3
H
H


28-118
CO2C2H5
C2H5
H
H


28-119
CO2C2H5
n-C3H7
H
H


28-120
CONHCH3
CH3
H
H


28-121
CONHC2H5
CH3
H
H


28-122
CON(CH3)2
CH3
H
H


28-123
CH3
CO2CH3
H
H


28-124
H
6-Cl—Py-3-yl
H
H










28-125
CH2CH2CH2
H
H


28-126
CH2CH2CH2
H
CH3


28-127
CH2CH2CH2
CH3
H


28-128
CH2CH2CH2CH2
H
H


28-129
CH2CH2CH2CH2
H
CH3


28-130
CH2CH2CH2CH2
CH3
H


28-131
CH2CH2CH2CH2
Ph
H











28-132
H
2-Cl—Ph
H
H


28-133
H
3-Cl—Ph
H
H


28-134
H
4-Br—Ph
H
H


28-135
H
4-CN—Ph
H
H


28-136
H
4-CH3—Ph
H
H


28-137
H
4-OCH3—Ph
H
H


28-138
H
4-OCF3—Ph
H
H


28-139
H
4-OCH2CF3—Ph
H
H





Note:


E is C(CH3)—NOCH3;


M is C6H3-3,4-(OCH3)2.






Table 29: When Ar is Ar3, Q is Q2, the substituents of presentitive compounds 29-1 to 29-131 are consistent with 28-1 to 28-139 in Table 28;
Table 30: When Ar is Ar3, Q is Q3, the substituents of presentitive compounds 30-1 to 30-131 are consistent with 28-1 to 28-139 in Table 28;
Table 31: When Ar is Ar3, Q is Q4, the substituents of presentitive compounds 31-1 to 31-131 are consistent with 28-1 to 28-139 in Table 28;
Table 32: When Ar is Ar3, Q is Q5, the substituents of presentitive compounds 32-1 to 32-131 are consistent with 28-1 to 28-139 in Table 28;
Table 33: When Ar is Ar3, Q is Q6, the substituents of presentitive compounds 33-1 to 33-131 are consistent with 28-1 to 28-139 in Table 28;
Table 34: When Ar is Ar3, Q is Q7, the substituents of presentitive compounds 34-1 to 34-131 are consistent with 28-1 to 28-139 in Table 28;
Table 35: When Ar is Ar3, Q is Q8, the substituents of presentitive compounds 35-1 to 35-131 are consistent with 28-1 to 28-139 in Table 28;
Table 36: When Ar is Ar3, Q is Q9, the substituents of presentitive compounds 36-1 to 36-131 are consistent with 28-1 to 28-139 in Table 28;
Table 37: When Ar is Ar3, Q is Q19, the substituents of presentitive compounds 37-1 to 37-131 are consistent with 28-1 to 28-139 in Table 28;
Table 38: When Ar is Ar3, Q is Q20, the substituents of presentitive compounds 38-1 to 38-131 are consistent with 28-1 to 28-139 in Table 28;
Table 39: When Ar is Ar3, Q is Q21, the substituents of presentitive compounds 39-1 to 39-131 are consistent with 28-1 to 28-139 in Table 28;
Table 40: When Ar is Ar3, Q is Q22, the substituents of presentitive compounds 40-1 to 40-131 are consistent with 28-1 to 28-139 in Table 28.
When Ar is Ar4, Q is Q1, the presentitive compounds 41-1 to 41-116 are listed in Table 41.







TABLE 41







substituents when Ar = Ar4








 












No.
R1
R2
R3
R4
R5





41-1
H
H
H
H
H


41-2
CH3
H
H
H
H


41-3
C2H5
H
H
H
H


41-4
i-C3H7
H
H
H
H


41-5
n-C3H7
H
H
H
H


41-6
n-C4H9
H
H
H
H


41-7
t-C4H9
H
H
H
H


41-8
OH
H
H
H
H


41-9
NH2
H
H
H
H


41-10
CN
H
H
H
H


41-11
NO2
H
H
H
H


41-12
CHO
H
H
H
H


41-13
CO2H
H
H
H
H


41-14
COCH3
H
H
H
H


41-15
CONH2
H
H
H
H


41-16
COOCH3
H
H
H
H


41-17
CH2COCH3
H
H
H
H


41-18
CH2—CH═CH2
H
H
H
H


41-19
C(CH3)2—CH═CH2
H
H
H
H


41-20
4-Cl—Ph
H
H
H
H


41-21
4-CH3—Ph
H
H
H
H


41-22
H
CH3
H
H
H


41-23
H
C2H5
H
H
H


41-24
H
i-C3H7
H
H
H


41-25
H
n-C3H7
H
H
H


41-26
H
n-C4H9
H
H
H


41-27
H
t-C4H9
H
H
H


41-28
H
OCH3
H
H
H


41-29
H
OC2H5
H
H
H


41-30
H
CH2Cl
H
H
H


41-31
H
CH2NH2
H
H
H


41-32
H
CH2CH2NH2
H
H
H


41-33
H
COOCH3
H
H
H


41-34
H
COCH3
H
H
H


41-35
H
CH2COCH3
H
H
H


41-36
H
OH
H
H
H


41-37
H
4-t-C4H9—Ph
H
H
H


41-38
H
4-Cl—Ph
H
H
H


41-39
H
4-CH3—Ph
H
H
H


41-40
H
H
CH3
H
H


41-41
H
H
C2H5
H
H


41-42
H
H
i-C3H7
H
H


41-43
H
H
n-C3H7
H
H


41-44
H
H
n-C4H9
H
H


41-45
H
H
t-C4H9
H
H


41-46
H
H
OH
H
H


41-47
H
H
NH2
H
H


41-48
H
H
CN
H
H


41-49
H
H
NO2
H
H


41-50
H
H
CHO
H
H


41-51
H
H
CO2H
H
H


41-52
H
H
COCH3
H
H


41-53
H
H
CH2N(CH3)2
H
H


41-54
H
H
CH2—CH═CH2
H
H


41-55
H
H
C(CH3)2—CH═CH2
H
H


41-56
H
H
F
H
H


41-57
H
H
Cl
H
H


41-58
H
H
Br
H
H


41-59
H
H
I
H
H


41-60
H
H
H
CH3
H


41-61
H
H
H
C2H5
H


41-62
H
H
H
i-C3H7
H


41-63
H
H
H
n-C3H7
H


41-64
H
H
H
n-C4H9
H


41-65
H
H
H
t-C4H9
H


41-66
H
H
H
OCH3
H


41-67
H
H
H
OC2H5
H


41-68
H
H
H
CH2Cl
H


41-69
H
H
H
COCH3
H


41-70
H
H
H
NH2
H


41-71
H
H
H
NO2
H


41-72
H
H
H
OH
H


41-73
H
H
H
OCOCH3
H


41-74
H
H
H
F
H


41-75
H
H
H
Cl
H


41-76
H
H
H
Br
H


41-77
H
H
H
I
H


41-78
H
H
H
CH2—CH═CH2
H


41-79
H
H
H
CH2—C≡CH
H


41-80
H
H
H
H
CH3


41-81
H
H
H
H
C2H5


41-82
H
H
H
H
i-C3H7


41-83
H
H
H
H
n-C3H7


41-84
H
H
H
H
n-C4H9


41-85
H
H
H
H
t-C4H9


41-86
H
H
H
H
OCH3


41-87
H
H
H
H
OC2H5


41-88
H
H
H
H
OH


41-89
H
H
H
H
C(NOCH3)CH3


41-90
H
H
H
H
F


41-91
H
H
H
H
Cl


41-92
H
H
H
H
Br


41-93
H
H
H
H
I


41-94
H
H
H
H
CH2—CH═C(CH3)2


41-95
H
CH3
H
H
CH3


41-96
H
Ph
H
H
CH3


41-97
H
Ph
H
H
OCH3


41-98
H
CH2Cl
H
H
Ph


41-99
H
H
CH3
H
CH3


41-100
H
H
OCH3
H
OCH3


41-101
CH3
H
H
OCH3
H


41-102
CH3
H
H
CH═CH2Ph
H


41-103
H
CH3
CH3
H
H


41-104
CH3
CH3
H
H
H


41-105
Ph
CH3
H
H
H


41-106
H
H
OCH3
H
OCH3


41-107
H
CH3
Cl
H
H


41-108
H
CH3
H
H
CH3


41-109
H
H
H
OCH3
OCH3


41-110
H
CH3
CH3
H
OCH3











41-111
CH2CH2CH2
H
H
H


41-112
CH2CH2CH2
H
H
CH3


41-113
CH2CH2CH2
H
H
OCH3


41-114
CH2CH2CH2CH2
H
H
H


41-115
CH2CH2CH2CH2
H
H
CH3


41-116
CH2CH2CH2CH2
H
H
OCH3









Table 42: When Ar is Ar4, Q is Q2, the substituents of presentitive compounds 42-1 to 42-116 are consistent with 41-1 to 41-116 in Table 41;
Table 43: When Ar is Ar4, Q is Q3, the substituents of presentitive compounds 43-1 to 43-116 are consistent with 41-1 to 41-116 in Table 41;
Table 44: When Ar is Ar4, Q is Q4, the substituents of presentitive compounds 44-1 to 44-116 are consistent with 41-1 to 41-116 in Table 41;
Table 45: When Ar is Ar4, Q is Q5, the substituents of presentitive compounds 45-1 to 45-116 are consistent with 41-1 to 41-116 in Table 41;
Table 46: When Ar is Ar4, Q is Q6, the substituents of presentitive compounds 46-1 to 46-116 are consistent with 41-1 to 41-116 in Table 41;
Table 47: When Ar is Ar4, Q is Q7, the substituents of presentitive compounds 47-1 to 47-116 are consistent with 41-1 to 41-116 in Table 41;
Table 48: When Ar is Ar4, Q is Q8, the substituents of presentitive compounds 48-1 to 48-116 are consistent with 41-1 to 41-116 in Table 41;
Table 49: When Ar is Ar3, Q is Q9, the substituents of presentitive compounds 49-1 to 49-116 are consistent with 41-1 to 41-116 in Table 41;
Table 50: When Ar is Ar3, Q is Q19, the substituents of presentitive compounds 50-1 to 50-116 are consistent with 41-1 to 41-116 in Table 41;
Table 51: When Ar is Ar3, Q is Q20, the substituents of presentitive compounds 51-1 to 51-116 are consistent with 41-1 to 41-116 in Table 41;
Table 52: When Ar is Ar3, Q is Q21, the substituents of presentitive compounds 52-1 to 52-116 are consistent with 41-1 to 41-116 in Table 41;
Table 53: When Ar is Ar3, Q is Q22, the substituents of presentitive compounds 53-1 to 53-116 are consistent with 41-1 to 41-116 in Table 41.
Some commercial (or under development) substituent benzyloxy group containing ether compounds used as fungicides in agrochemical field are summarized as follows (Table 54):
















azoxystrobin
kresoxim-methyl
metominostrobin
picoxystrobin
trifloxstrobin


pyraoxystrobin
Dimoxystrobin
(fluoxastrobin)
orysastrobin
enoxastrobin



(SSF 129)


flufenoxystrobin
(pyrametostrobin)
(triclopyricarb)
fenaminstrobin
pyraclostrobin









The most preferred substituent benzyloxy group containing ether compounds applied as antitumor drugs of general formula I are: compounds 28-5 (jiaxiangjunzhi), 28-72 (coumoxystrobin), 28-18, 28-128, 28-129 and pyraoxystrobin.
The compounds having formula I in present invention have been reported in prior art, which are commercial available or can be prepared according to the following literatures U.S. Pat. No. 7,642,364, CNP1869032, Pest Manag. Sci. 2011, 67, 647, Nat. Prod. Commun. 2011, 6, 1917, Chin. Chem. Lett. 2011, 22, 663, Chin. J. Pestic. 2011, 50, 90.
The present invention includes the formulations, which were made from the compounds having the general formula I as active ingredient, and preparation thereof. The preparation of formulations: Dissolve the compounds of present invention in water soluble organic solvents, the non-ionicity of surfactant, water soluble lipid, all kinds of cyclodextrin, fatty acid, fatty acid ester, phospholipids or their combination solvents, then 1-20% of carbohydrates were obtained by adding physiological saline. Mentioned organic solvents include polyethylene glycol (PEG), ethanol, propylene glycol or their combination solvents.
The compounds having the general formula I in present invention and their isomers and prodrug can be used to prepare the drugs or formulations to cure, prevent or alleviate cancer. The active ingredients are composed of one or more than two substituent benzyloxy group containing ether compounds having the general formula I. Especially to cure or alleviate the cancer causing by cancer cells of human tissue or organ. The preferred cancers are: colon cancer, liver cancer, lymph cancer, lung cancer, esophageal cancer, breast cancer, central nervous system cancer, melanoma, ovarian cancer, cervical cancer, renal cancer, leukemia, prostatic cancer, pancreatic cancer, bladder cancer, rectal cancer, or stomach cancer, etc.
The compounds in present invention can be used as active ingredients of antitumor drug, which can be used alone or combined with other antitumor/antiviral drugs. The drug combination process in present invention, using at least one of the compounds and its active derivatives with other one or more antitumor/antiviral drugs, are used together to increase the overall effect. The dose and drug administration time of combination therapy are based on the most reasonable treatment effect in the different situations.
The formulations include the effective dose of the compounds having general formula I. The “effective dose” refers to the compound dosage, which are effective to cure cancer. The effective dose or dose can be different based on the suggestions of experienced person at different conditions. For instance, the different usage of drug based on different cancers; the dose of drug also can be changed based on whether it shares with other therapeutic method, such as antitumor or antiviral drugs. The drug can be prepared for any useable formulations. The salts of compounds also can be used if the alkaline or acidic compounds can formed the non-toxic acids or salts. The organic acids/salts in pharmacy include anion salts, which are formed with acids, such as p-toluenesulfonic acid, methylsulfonic acid, acetic acid, benzoic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, ascorbic acid or glycerophosphoric acid; the inorganic salts include chloride, bromide, fluoride, iodide, sulfate, nitrate, bicarbonate, carbonate or phosphate. For example, the alkaline compounds, such as amines can form salts with suitable acids; acids can form salts with alkalis or alkaline earth.
The compounds in present invention having general formula I general easily dissolve in organic solvent, water soluble solvent and their mixture with water. The water soluble solvents prefer alcohol, polyethylene glycol, N-methyl-2-pyrrolidone, N, N-dimethyl acetamide, N, N-dimethyl formamide, dimethylsulfoxide, acetonitrile and their mixture. Mentioned alcohols prefer methanol, ethanol, isopropanol, glycerol or ethylene glycol. The compounds in present invention mix with common drug carrier to form formulations. Dissolve the compounds of present invention in water soluble organic solvents, aprotic solvent, water soluble lipid, cyclodextrin, fatty acid, phospholipids or their combination solvents, then 1-20% of carbohydrates were obtained by adding physiological saline, such as glucose aqueous solution. The stability formulations made by this way are used for animal and clinical.
The drugs were made from the active ingredients of general formula I compounds, which can dose by oral medication or parenteral route, also by implantable medication pump and other methods. Where the parenteral route refer to injection or drip technology through subcutaneous intradermal, intramuscular, intravenous, arteries, atrium, synovium, sternum, intrathecal, wound area, encephalic, etc. The formulations were mixed using conventional method by technicist, which are used for animal and clinical, including tablets, pills, capsule, granule, syrup, injection, freeze-dried powder injection, emulsion, powder, freeze-dried powder, drop pill, milk suspension, aqueous suspension, colloid, colloidal solution, sustained-release suspensions, nanoparticle or other formulations.
The compounds having the general formula I in present invention can be used to cure or alleviate the cancer causing by cancer cells of human tissue or organ. The cancers include but not limited to colon cancer, liver cancer, lymph cancer, lung cancer, esophageal cancer, breast cancer, central nervous system cancer, melanoma, ovarian cancer, cervical cancer, renal cancer, leukemia, prostatic cancer, pancreatic cancer, bladder cancer, rectal cancer or stomach cancer.


DETAILED DESCRIPTION OF THE INVENTION
The present invention is illustrated by the following examples, but without being restricted thereby. (All raw materials are commercially available unless otherwise specified.)
Antitumor Activity Bioassay
In vitro Cell inhibition assay is as follows:
The human cancer cell lines used for this assay were bladder cancer J82, T24, prostate cancer LNCap, PC-3, lung cancer A549, H157, H460, H520, colon cancer HCT8, HCT116, RkO, and leukemia HL-60, etc.
Example 1
In vitro cell culture technology was selected for the determination of inhibition rate bladder cancer cell lines J82 and T24, prostate cancer cell lines LNCap and PC-3, lung cancer cell lines A549, H157, H460 and H520. 1000 to 3000 cells were inoculated to 24-well plate, followed by addition of 1 mL culture medium well known to researchers in this field to each well, the cells were cultured in 5% incubator for 24 hours at 37° C., then the different concentration compounds and controls were added to each well. It should be noted that the added volume is not more than 0.5% of total volume. After completion of addition, the cells continued being cultured in incubator for one week, the culture medium was removed and washed by cold PBS of 1 mL once, and then fixed for 10 minutes at room temperature with 1% formalin, followed by wash with PBS of 1 mL. After fixation, stain was carried out with 0.1% crystal violet for 30 minutes. 0.1% crystal violet was recycled. The stained cells were washed gently with deionized water, dried at room temperature and kepted. The inhibition rate was calculated according to the foiling equation. The controls are Selumetinib (AZD6244), Gefitinib, Cisplatin.

Inhibition rate=number of left cells each treatment/number of left cells of untreated control×100%

At the concentration of 10 μM, the inhibition rate of compounds of this invention against all tested cell lines attached 90%-100%, some of them were further tested at lower concentration and the comparative bioassay was conducted with the controls selumetinib (AZD6244), gefitinib, Cisplatin at the same time, part of test results are listed in Table 55:







TABLE 55







Inhibition rate on human cancer cells











Concentration (μM)/Inhibition (%)













Cell line
Compound No
5.0
2.5
1.0
0.5
0.25
















J82
28-5
100
100
80
/
/



28-72
100
100
95
90
70



Pyraoxystrobin
100
100
100
100
70



selumetinib
70
/
/
/
/



Cisplatin
20
5
0
0
0



Compound A
100
100
95
50
0



Compound B
100
95
90
50
0



Flufenoxystrobin








Azoxystrobin
0
/
/
/
/


T24
28-5
100
100
100
100
100



28-72
100
100
100
100
100



Pyraoxystrobin
100
100
100
100
100



Selumetinib
70
/
/
/
/



Cisplatin
20
5
0
0
0



Compound A
100
100
100
0
/



Compourtd B
100
100
100
5
0



Flufenoxystrobin








Azoxystrobin
0
/
/
/
/


LNCap
28-5
100
100
100
/
/



28-72
100
100
100
100
100



Pyraoxystrobin
100
100
100
100
100



selumetinib
20
/
/
/
/



Compound A
100
100
100
0
/



Compourtd B
100
50
0
/
/



Flufenoxystrobin








Azoxystrobin
0
/
/
/
/


PC-3
28-5
100
100
100
/
/



28-72
100
100
100
100
100



Pyraoxystrobin
100
100
100
100
100



Selumetinib
0
/
/
/
/



Compound A
100
100
85
0
/



Compourtd B
100
100
50
/
/



Flufenoxystrobin








Azoxystrobin
0
/
/
/
/


A549
28-5
100
100
80
/
/



28-7
90
70
/
/
/



28-12
100
95
80
/
/



28-18
100
100
100
90
/



28-27
95
90
80
/
/



28-29
95
/
/
/
/



28-33
99
95
80
/
/



28-34
100
95
90
/
/



28-50
90
/
/
/
/



28-52
100
100
95
90
/



28-72
100
100
95
90
/



28-75
90
/
/
/
/



28-126
90
85
/
/
/



28-128
100
100
100
100
70



28-129
100
100
100
95
90



28-132
90
/
/
/
/



28-133
100
100
/
/
/



28-134
100
100






28-135
80
/
/
/
/



28-136
100
100
/
/
/



28-137
100
100
/
/
/



28-137
100
100
/
/
/



Selumetinib
10
0
0
0
0



Gefitinib
20
10
0
0
0



Cisplatin
80
30
5
0
0


H157
28-5
100
100
100
100
/



28-72
100
100
100
100
>90



AZD6244
20
/
/
/
/


H460
28-2
95
/
/
/
/



28-5
100
100
100
100
/



28-7
95
80
/
/
/



28-12
95
90
75
/
/



28-18
95
95
95
90
80



28-27
95
95
80
/
/



28-29
95
90
70
/
/



28-33
95
95
90
/
/



28-34
95
95
93
/
/



28-41
85
75
/
/
/



28-50
95
90
70
/
/



28-52
100
100
100
90
60



28-72
100
100
100
100
95



28-75
95
90
70
/
/



28-124
75
/
/
/
/



28-126
95
90
/
/
/



28-128
100
100
100
100
80



28-129
100
100
95
70
/



32-5
95
/
/
/
/



32-6
85
/
/
/
/



Selumetinib
60
0
0
0
0



Gefitinib
95
0
0
0
0



Cisplatin
90
30
5
0
0


H520
28-5
100
100
90
80
70



28-7
100
80
/
/
/



28-12
100
100
50
/
/



28-18
100
100
100
95
50



28-27
100
100
100
95
/



28-29
100
70
70
40
30



28-33
100
90
/
/
/



28-34
100
100
99
70
/



28-41
70
/
/
/
/



28-50
100
80
60
50
30



28-52
100
100
100
100
70



28-72
100
100
100
100
>90



28-75
100
80
/
/
/



28-124
70
/
/
/
/



28-126
95
90
70
/
/



28-128
100
100
100
100
70



28-129
100
100
100
95
85



Selumetinib
20
/
/
/
/



Gefitinib
5
0
0
0
0



Cisplatin
50
30
20
5
0


HCT 8
28-72
100
100
100
95
/



28-128
100
100
100
100
95



28-129
100
100
100
95
80



Selumetinib
50
40
20
/
/



Gefitinib
/
10
5
0
/



Cisplatin
90
70
50
10
5


HCT 116
28-72
100
100
99
95
80



28-128
100
100
100
100
95



28-129
100
100
100
95
90



Selumetinib
90
85
80
75
50



Gefitinib
30
5
0
0
0



Cisplatin
50
20
5
0
0


RkO
28-72
100
100
100
100
95



28-128
100
100
100
100
99



28-129
100
100
100
99
85



Selumetinib
95
90
85
80
30



Gefitinib
/
80
75
70
50



Cisplatin
70
50
10
5
0





Note:


1.“/” stands for no data.


2.bladder cancer cell lines J82    T24, prostate cancer cell lines LNCap    PC-3, lung cancer cell lines A549, H157    H460    H520, clon cancer cell lines HCT8, HCT116, RkO, the culture medium for all cell lines is RMPI-1640.






Example 2
The inhibition rate of human leukemia HL-60 cells was evaluated by regular MTT method. The human leukemia HL-60 cells were picked up from cell incubator, after washed for twice using PBS, cells were digested by 0.25% trypsin, and then add medium to terminate the digestion. After cells were collected using centrifuge and re-suspended, counting cells under inverted microscope and adding medium to make a density which was 5×104 cells/mL. After 100 μL aliquots were added to each well of 96-well microtiter plates, cells were cultured in 5% incubator for overnight at 37° C., then the different concentration compounds were added to each well. After incubation for 48 h, MTT solution was added to each well and plates were then incubated for 4 h. The MTT tetrazolium was reduced to formazan by living cells. Then the formazan crystals were dissolved though adding DMSO to each well. The absorbance was read at 570 nm with a microplate reader.
Part of the test results are listed in Table 56:







TABLE 56







Proliferation inhibitory effect on human leukemia HL-60 cell (%)









Concentration (μM)












Compound No.
100
10
1
















 2-1
48.8
0
0



28-2
71.3
49.2
6.0



28-3
58.8
33.4
4.1



28-5
73.8
59.3
31.7 



28-6
52.0
53.0
48.2



28-7
83.9
71.0
42.3



28-24
86.7
44.5
10.8



28-27
83.9
79.9
59.0



28-38
63.7
72.9
77.5



28-50
84.8
83.1
47.1



28-68
84.4
62.0
54.6



28-71
50.3
48.2
40.9



28-72
54.4
47.9
45.3



28-79
71.2
53.1
28.8



28-124
27.8
29.3
0.5



28-125
85.0
73.8
47.0



15-22
86.8
51.8
50.3







Note:



the culture medium for human leukemia HL-60 is OPTI-MEM.

## Claims

1. A method of treating a subject having a cancer selected from the group consisting of colon cancer, lung cancer, leukemia, prostatic cancer, and bladder cancer, which comprises administering to the subject a substituent benzyloxy group containing ether compound as an antitumor agent, said substituent benzyloxy group containing either compound having general formula I:



wherein:
Ar is selected from one of the following groups, Ar2 to Ar3:




Q is selected from one of the following groups, Q1 to Q22:







R1, R2, R3, R4, R5, and R6, are each independently H, halo, CN, NO2, OH, NH2, CHO, CO2H, CO2Na, CO2NH4, C1-C12alkyl, C1-C12haloalkyl, C3-C8cycloalkyl, C1-C12alkoxy, C1-C12haloalkoxy, C1-C12alkylthio, C1-C12haloalkylthio, C1-C12alkoxyC1-C12alkyl, haloC1-C12alkoxyC1-C12alkyl, C1-C12alkoxyC1-C12alkoxy, haloC1-C12alkoxyC1-C12alkoxy, C1-C12alkylthioC1-C12alkyl, haloC1-C12alkylthioC1-C12alkyl, C1-C12alkylamino, C1-C12haloalkylamino, C2-C12dialkylamino, C2-C12halodialkylamino, piperidinyl, pyrrolidinyl, N-methylpiperidinyl, morpholinyl, C2-C12alkenyl, C2-C12haloalkenyl, C2-C12alkynyl, C2-C12haloalkynyl, C2-C12alkenyloxy, C2-C12haloalkenyloxy, C2-C12alkynyloxy, C2-C12haloalkynyloxy, C1-C12alkylsulfonyl, C1-C12haloalkylsulfonyl, C1-C12alkylsulfinyl, C1-C12haloalkylsulfinyl, C1-C12alkylcarbonyl, C1-C12haloalkylcarbonyl, C1-C12alkylcarbonyloxy, C1-C12alkylcarbonylamino, C1-C12alkylsulfonyloxy, C1-C12alkoxycarbonyl, C1-C12haloalkoxycarbonyl, C1-C12alkylamlinosulfonyl, C1-C12alkoxycarbonylamino, C1-C12alkoxycarbonylC1-C12alkyl, C1-C12alkoxycarbonylC1-C12alkoxy, aminoC1-C12alkyl, C1-C12alkylaminoC1-C12alkyl, C2-C12dialkylaminoC1-C12alkyl, C(═O)NR10R11, OC(═O)NR10R11, C(═S)NR10R11, SO2NR10R11, C(═NOR9)R8, or R7; or R1 and R2 are linked with a carbon atom to form a six-membered ring;
R7 is unsubstituted or substituted phenyl, phenyloxy, phenyloxy C1-C12alkyl, phenylcarbonyl, phenyloxycarbonyl, phenylaminocarbonyl, phenylC1-C12alkyl, phenylC1-C12alkoxy, phenylC1-C12alkoxyC1-C12alkyl, naphthyl, naphthyloxy, naphthyloxy C1-C12alkyl, naphthylcarbonyl, naphthyl C1-C12alkyl, naphthyl C1-C12alkoxy, naphthyl C1-C12alkoxyC1-C12alkyl, heteroaryl, heteroaryloxy, heteroarylC1-C12alkoxyC1-C12alkyl, heteroaryloxyC1-C12alkyl, heteroarylcarbonyl, heteroaryloxycarbonyl, heteroarylaminocarbonyl, heteroarylC1-C12alkyl or heteroarylC1-C12alkoxy, which may be optionally substituted by 1 to 5 substituents selected from the group consisting of: halo, NO2, CN, SH, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkylthio, C1-C6haloalkylthio, C2-C6alkenyl, C2-C6haloalkenyl, C2-C6alkynyl, C2-C6haloalkynyl, C3-C6alkenyloxy, C3-C6haloalkenyloxy, C3-C6alkynyloxy, C3-C6haloalkynyloxy, C1-C6alkylsulfinyl, C1-C6haloalkylsulfinyl, C1-C6alkylsulfonyl, C1-C6haloalkylsulfonyl, C1-C6alkoxyC1-C6alkyl, C1-C6alkylcarbonyl, C1-C6haloalkylcarbonyl, C1-C6alkylcarbonyloxy, C1-C6alkylcarbonylamino, C1-C6alkylsulfonyloxy, C1-C6alkoxycarbonyl, C1-C6alkoxyC1-C6alkoxy, C1-C6alkoxycarbonylC1-C6alkyl, C1-C6alkoxycarbonylamino, C1-C6alkoxycarbonylC1-C6alkoxy, CHO, CO2H, CO2Na, CO2NH4, NR10R11, C(═O)NR10R11, OC(═O)NR10R11, C(═S)NR10R11, and SO2NR10R11;
R8 and R9 are each independently H, C1-C6alkyl, aryl, or aryl C1-C6alkyl;
R10 and R11 are each independently H, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkylthio, C1-C6haloalkylthio, or C3-C8cycloalkyl;
and stereoisomers thereof.

2. The method according to claim 1, wherein
Ar is Ar2 or Ar3;
Q is Q1, Q2, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q11, Q20, Q21, or Q22;
R1, R2, R3, R4, R5, and R6 are each independently H, halo, CN, NO2, OH, NH2, CHO, CO2H, CO2Na, CO2NH4, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkylthio, C1-C6haloalkylthio, C1-C6alkoxyC1-C6alkyl, haloC1-C6alkoxyC1-C6alkyl, C1-C6alkoxyC1-C6alkoxy, haloC1-C6alkoxyC1-C6alkoxy, C1-C6alkylthioC1-C6alkyl, haloC1-C6alkylthioC1-C6alkyl, C1-C6alkylamino, C1-C6haloalkylamino, C2-C8dialkylamino, C2-C8halodialkylamino, piperidinyl, pyrrolidinyl, N-methylpiperidinyl, morpholinyl, C2-C6alkenyl, C2-C6haloalkenyl, C2-C6alkynyl, C2-C6haloalkynyl, C2-C6alkenyloxy, C2-C6haloalkenyloxy, C2-C6alkynyloxy, C2-C6haloalkynyloxy, C1-C6alkylsulfonyl, C1-C6haloalkylsulfonyl, C1-C6alkylsulfinyl, C1-C6haloalkylsulfinyl, C1-C6alkylcarbonyl, C1-C6haloalkylcarbonyl, C1-C6alkylcarbonyloxy, C1-C6alkylcarbonylamino, C1-C6alkylsulfonyloxy, C1-C6alkoxycarbonyl, C1-C6haloalkoxycarbonyl, C1-C6alkylaminosulfonyl, C1-C6alkoxycarbonylamino, C1-C6alkoxycarbonylC1-C6alkyl, C1-C6alkoxycarbonylC1-C6alkoxy, aminoC1-C6alkyl, C1-C6alkylaminoC1-C6alkyl, C2-C8dialkylaminoC1-C6alkyl, C(═O)NR10R11, OC(═O)NR10R11, C(═S)NR10R11, SO2NR10R11, C(═NOR9)R8, or R7; or R1 and R2 are linked with a carbon atom to form a six-membered ring;
R7 is unsubstituted or substituted phenyl, phenyloxy, phenyloxy C1-C6alkyl, phenylcarbonyl, phenyloxycarbonyl, phenylaminocarbonyl, phenylC1-C6alkyl, phenylC1-C6alkoxy, phenylC1-C6alkoxyC1-C6alkyl, naphthyl, naphthyloxy, naphthyloxy C1-C6alkyl, naphthylcarbonyl, naphthyl C1-C6alkyl, naphthyl C1-C6alkoxy, naphthylC1-C6alkoxyC1-C6alkyl, heteroaryl, heteroaryloxy, heteroalyC1-C6alkoxyC1-C6alkyl, heteroaryloxyC1-C6alkyl, heteroarylcarbonyl, heteroaryloxycarbonyl, heteroarylaminocarbonyl, heteroaylC1-C6alkyl or heteroarylC1-C6alkoxy, which i may be optionally substituted by 1 to 5 substituents selected from the group consisting of: halo, NO2, CN, SH, C1-C4alkyl, C1-C4 haloalkyl, C3-C6cycloalkyl, C1-C4alkoxy, C1-C4haloalkoxy, C1-C4alkylthio, C1-C4haloalkylthio, C2-C4alkenyl, C2-C4haloalkenyl, C2-C4alkynyl, C2-C4haloalkynyl, C3-C4alkenyloxy, C3-C4haloalkenyloxy, C3-C4alkynyloxy, C3-C4haloalkynyloxy, C1-C4alkylsulfinyl, C1-C4haloalkylsulfinyl, C1-C4alkylsulfonyl, C1-C4haloalkylsulfonyl, C1-C4alkoxyC1-C4alkyl, C1-C4alkylcarbonyl, C1-C4haloalkylcarbonyl, C1-C4alkylcarbonyloxy, C1-C4alkylcarbonylamino, C1-C4alkylsulfonyloxy, C1-C4alkoxycarbonyl, C1-C4alkoxyC1-C4alkoxy, C1-C4alkoxycarbonylC1-C4alkyl, C1-C4alkoxycarbonylamino, C1-C4alkoxycarbonylC1-C4alkoxy, CHO, CO2H, CO2Na, CO2NH4, NR10R11, C(O)NR10R11, OC(═O)NR10R11, C(═S)NR10R11, and SO2NR10R11;
R8 and R9 are each independently H, C1-C4alkyl, aryl, or aryl C1-C4alkyl;
R10 and R11 are each independently H, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy, C1-C4haloalkoxy, C1-C4alkylthio, C1-C4haloalkylthio, or C3-C6cycloalkyl.

3. The method according to claim 2, wherein
Ar is Ar2 or Ar3;
Q is Q1, Q2, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q19, Q20, Q21, or Q22;
R1, R2, R3, R4, R5, and R6 are each independently H, halo, CN, NO2, OH, NH2, CHO, CO2H, CO2Na, CO2NH4, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, C1-C4alkoxy, C1-C4haloalkoxy, C1-C4alkylthio, C1-C4haloalkylthio, C1-C4alkoxyC1-C4alkyl, haloC1-C4alkoxyC1-C4alkyl, C1-C4alkoxyC1-C4alkoxy, haloC1-C4alkoxyC1-C4alkoxy, C1-C4alkylthioC1-C4alkyl, haloC1-C4alkylthioC1-C4alkyl, C1-C4alkylamino, C1-C4haloalkylamino, C2-C6dialkylamino, C2-C6halodialkylamino, piperidinyl, pyrrolidinyl, N-methylpiperidinyl, morpholinyl, C2-C4alkenyl, C2-C4haloalkenyl, C2-C4alkynyl, C2-C4haloalkynyl, C2-C4alkenyloxy, C2-C4haloalkenyloxy, C2-C4alkynyloxy, C2-C4haloalkynyloxy, C1-C4alkylsulfonyl, C1-C4haloalkylsulfonyl, C1-C4alkylsulfinyl, C1-C4haloalkylsulfinyl, C1-C4alkylcarbonyl, C1-C4haloalkylcarbonyl, C1-C4alkylcarbonyloxy, C1-C4alkylcarbonylamino, C1-C4alkylsulfonyloxy, C1-C4alkoxycarbonyl, C1-C4haloalkoxycarbonyl, C1-C4alkylaminosulfonyl, C1-C4alkoxycarbonylamino, C1-C4alkoxycarbonylC1-C4alkyl, C1-C4alkoxycarbonylC1-C4alkoxy, aminoC1-C4alkyl, C1-C4alkylaminoC1-C4alkyl, C2-C6dialkylaminoC1-C4alkyl, C(═O)NR10R11, OC(═O)NR10R11, C(═S)NR10R11, SO2NR10R11, C(═NOR9)R8, or R7; or R1 and R2 are linked with a carbon atom to form a saturated six-membered ring;
R7 is unsubstituted or substituted phenyl, phenyloxy, phenyloxy C1-C4alkyl, phenylcarbonyl, phenyloxycarbonyl, phenylaminocarbonyl, phenylC1-C4alkyl, phenylC1-C4alkoxy, phenylC1-C4alkoxyC1-C4alkyl, naphthyl, naphthyloxy, naphthyloxy C1-C4alkyl, naphthylcarbonyl, naphthyl C1-C4alkyl, naphthyl C1-C4alkoxy, naphthylC1-C4alkoxyC1-C4alkyl, heteroaryl, heteroaryloxy, heteroarylC1-C4alkoxyC1-C4alkyl, heteroaryloxyC1-C4alkyl, heteroarylcarbonyl, heteroaryloxycarbonyl, heteroarylaminocarbonyl, heteroarylC1-C4alkyl, or heteroarylC1-C4alkoxy, which may be optionally substituted by 1 to 5 substituents selected from the group consisting of: halo, NO2, CN, SH, C1-C4alkyl, C1-C4 haloalkyl, C3-C6cycloalkyl, C1-C4alkoxy, C1-C4 haloalkoxy, C1-C4alkylthio, C1-C4haloalkylthio, C2-C4alkenyl, C2-C4haloalkenyl, C2-C4alkynyl, C2-C4haloalkynyl, C3-C4alkenyloxy, C3-C4haloalkenyloxy, C3-C4alkynyloxy, C3-C4 haloalkynyloxy, C1-C4alkylsulfinyl, C1-C4haloalkylsulfinyl, C1-C4alkylsulfonyl, C1-C4haloalkylsulfonyl, C1-C4alkoxyC1-C4alkyl, C1-C4alkylcarbonyl, C1-C4haloalkylcarbonyl, C1-C4alkylcarbonyloxy, C1-C4alkylcarbonylamino, C1-C4alkylsulfonyloxy, C1-C4alkoxycarbonyl, C1-C4alkoxyC1-C4alkoxy, C1-C4alkoxycarbonylC1-C4alkyl, C1-C4alkoxycarbonylamino, C1-C4alkoxycarbonylC1-C4alkoxy, CHO, CO2H, CO2Na, CO2NH4, NR10R11, C(═O)NR10R11, OC(═O)NR10R11, C(═S)NR10R11, and SO2NR10R11;
R8 and R9 is are each independently H, C1-C4alkyl, aryl, or aryl C1-C4alkyl;
R10 and R11 are each independently H, C1-C4alkyl, C1-C4 haloalkyl, C1-C4alkoxy, C1-C4 haloalkoxy, C1-C4alkylthio, C1-C4 haloalkylthio, or C3-C6cycloalkyl.

4. The method according to claim 3, wherein
Ar is Ar2 or Ar3;
Q is Q1, Q2, Q3, Q4, Q5, Q6, Q7, or Q8;
R1, R2, R3, R4, R5, and R6 are each independently H, halo, CN, C1-C6alkyl, C1-C4haloalkyl, C3-C6cycloalkyl, C1-C4alkoxy, C1-C4haloalkoxy, C1-C4alkylthio, A C1-C4alkoxyC1-C4alkyl, C1-C4alkylamino, C2-C6dialkylamino, C1-C4alkylsulfonyl, or R7; or R1 and R2 are linked with a carbon atom to form a saturated six-membered ring;
R7 is unsubstituted or substituted phenyl, benzyl, phenylethyl or heteroaryl, which may be optionally substituted by 1 to 5 substituents selected from the group consisting of: halo, NO2, CN, C1-C4alkyl, C1-C4 haloalkyl, C1-C4alkoxy, and C1-C4 haloalkoxy.

5. The method according to claim 4, wherein
Ar is Ar2 or Ar3;
Q is Q1;
R1, R2, R3, R4, R5, and R6 are each independently H, halo, CN, C1-C6alkyl, C1-C4haloalkyl, or R7; or R1 and R2 are linked with a carbon atom to form a saturated six-membered ring;
R7 is unsubstituted or substituted phenyl, benzyl, or heteroaryl, which may be optionally substituted by 1 to 5 substituents selected from the group consisting of: halo, NO2, CN, C1-C4alkyl, C1-C4 haloalkyl, C1-C4alkoxy, and C1-C4 haloalkoxy.

6. The method according to claim 5, wherein
Ar is Ar3;
Q is Q1;
R1, R2, R3, R4, R5, and R6 are each independently H, halo, CN, C1-C6alkyl, C1-C4haloalkyl, or R7; or R1 and R2 are linked with a carbon atom to form a saturated six-membered ring;
R7 is unsubstituted or substituted phenyl, benzyl, or heteroaryl, which may be optionally substituted by 1 to 5 substituents selected from the group consisting of: halo, NO2, CN, C1-C4alkyl, C1-C4 haloalkyl, C1-C4alkoxy, and C1-C4 haloalkoxy.

7. The method according to claim 6, wherein
Ar is Ar3;
Q is Q1;
R1 is H, halo, or C1-C6alkyl;
R2 is C1-C4alkyl, C1-C4haloalkyl, or R7;
or R1 and R2 are linked with a carbon atom to form a saturated six-membered ring;
R3 and R4 are H;
R6 is H or C1-C4alkyl;
R7 is unsubstituted or substituted phenyl, which may be optionally substituted by 1 to 3 substituents selected from the group consisting of: halo, CN, C1-C4alkyl, C1-C4 haloalkyl, C1-C4alkoxy, and C1-C4 haloalkoxy.

8. The method according to claim 7, wherein
Ar is Ar3;
Q is Q1;
R1 is H, halo, or C1-C6alkyl;
R2 is C1-C4alkyl or R7;
or R1 and R2 are linked with a carbon atom to form a saturated six-membered ring;
R3 and R4 are H;
R6 is H or C1-C4alkyl;
R7 is unsubstituted or substituted phenyl, which may be optionally substituted by 1 to 2 substituents selected from the group consisting of: halo, C1-C4alkyl, C1-C4alkoxy, and C1-C4 haloalkoxy.

9. The method according to claim 8, wherein
Ar is Ar3;
Q is Q1;
R1 is H, F, or C1-C4alkyl;
R2 is C1-C4alkyl or phenyl;
or R1 and R2 are linked with a carbon atom to form a saturated six-membered ring;
R3 and R4 are H;
R6 is H or CH3.

10. The method according to claim 9, wherein
Ar is Ar3;
Q is Q1;
R1 is H or C1-C4alkyl;
R2 is CH3 or phenyl;
or R1 and R2 are linked with a carbon atom to form a saturated six-membered ring;
R3, R4, R6 are H.

11. The method according to claim 1, wherein the substituent benzyloxy group containing ether compound is administered, as an active ingredient, orally or parentally, or by implantable medication pump administration.

12. The method according to claim 11, wherein the substituent benzyloxy group containing ether compound is administered as an active ingredient in the form of a tablet, a pill, a capsule, a granule, a syrup, an injection, or a freeze-dried powder injection.

13. The method according to claim 12, two or more of the substituted benzyloxy group containing ether compounds are provided as me active ingredient.